These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31353002)

  • 1. External Validation of the ORBIT Bleeding Score and the HAS-BLED Score in Nonvalvular Atrial Fibrillation Patients Using Direct Oral Anticoagulants (Asian Data from the DIRECT Registry).
    Mori N; Sotomi Y; Hirata A; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Oct; 124(7):1044-1048. PubMed ID: 31353002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants.
    Wattanaruengchai P; Nathisuwan S; Karaketklang K; Wongcharoen W; Phrommintikul A; Lip GYH
    Br J Clin Pharmacol; 2022 May; 88(5):2203-2212. PubMed ID: 34783372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative validation of HAS-BLED, GARFIELD-AF and ORBIT bleeding risk scores in Asian people with atrial fibrillation treated with oral anticoagulant: A report from the COOL-AF registry.
    Chichareon P; Winijkul A; Lip GYH; Krittayaphong R
    Br J Clin Pharmacol; 2023 Aug; 89(8):2472-2482. PubMed ID: 36942465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Sanmartin Fernández M; Arribas F; Masjuan J; Barrios V; Cosin-Sales J; Freixa-Pamias R; Recalde E; Pérez-Cabeza AI; Manuel Vázquez Rodríguez J; Ràfols Priu C; Anguita Sánchez M; Lip GYH; Marin F
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):38-46. PubMed ID: 36318457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: A report from a prospective European observational registry.
    Mei DA; Imberti JF; Bonini N; Romiti GF; Corica B; Proietti M; Vitolo M; Lip GYH; Boriani G
    Eur J Intern Med; 2024 Oct; 128():63-70. PubMed ID: 38969571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry.
    Proietti M; Romiti GF; Vitolo M; Potpara TS; Boriani G; Lip GYH
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):778-786. PubMed ID: 34555148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
    O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
    Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose of Direct Oral Anticoagulants and Adverse Outcomes in Asia.
    Ohno J; Sotomi Y; Hirata A; Sakata Y; Hirayama A; Higuchi Y
    Am J Cardiol; 2021 Jan; 139():50-56. PubMed ID: 33065084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    Am J Med; 2018 May; 131(5):574.e13-574.e27. PubMed ID: 29274754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldan V; Vicente V; Valdés M; Marín F; Lip GYH
    Thromb Haemost; 2017 Oct; 117(10):1848-1858. PubMed ID: 28799620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.
    Senoo K; Lip GY
    Int J Cardiol; 2016 Oct; 221():379-82. PubMed ID: 27409565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
    Senoo K; Proietti M; Lane DA; Lip GY
    Am J Med; 2016 Jun; 129(6):600-7. PubMed ID: 26482233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.
    Roldán V; Marín F; Fernández H; Manzano-Fernandez S; Gallego P; Valdés M; Vicente V; Lip GYH
    Chest; 2013 Jan; 143(1):179-184. PubMed ID: 22722228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-related difference in bleeding and thromboembolic risks in patients with atrial fibrillation treated with direct oral anticoagulants.
    Matsumura M; Sotomi Y; Hirata A; Sakata Y; Hirayama A; Higuchi Y
    Heart Vessels; 2022 Mar; 37(3):467-475. PubMed ID: 34427750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.
    Chan YH; Lee HF; Chao TF; Wu CT; Chang SH; Yeh YH; See LC; Kuo CT; Chu PH; Wang CL; Lip GYH
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):701-710. PubMed ID: 31745687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores.
    Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Romiti GF; Marin F; Lip GYH
    J Am Heart Assoc; 2018 Sep; 7(18):e009766. PubMed ID: 30371183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.